Security Snapshot

CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX) Institutional Ownership

CUSIP: 230770109

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

27

Shares (Excl. Options)

2,957,494

Price

$3.98

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common stock
Symbol
CPIX on Nasdaq
Shares outstanding
15,075,924
Price per share
$3.14
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,957,494
Total reported value
$11,770,877
% of total 13F portfolios
0%
Share change
-448,563
Value change
-$1,253,172
Number of holders
27
Price from insider filings
$3.14
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CPIX - CUMBERLAND PHARMACEUTICALS INC - Common stock is tracked under CUSIP 230770109.
  • 27 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 27 to 12 between Q4 2025 and Q1 2026.
  • Reported value moved from $11,770,877 to $2,924,086.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 27 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 230770109?
CUSIP 230770109 identifies CPIX - CUMBERLAND PHARMACEUTICALS INC - Common stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KAZIMI A J 38% -5.9% $27,324,812 +$409,974 5,789,155 +1.5% A.J. Kazimi 30 Jan 2026
Ikarian Capital, LLC 4.9% $3,545,020 730,932 Ikarian Capital, LLC 31 Mar 2025
INTEGRATED CORE STRATEGIES (US) LLC 4% -30% $1,618,467 -$571,171 598,634 -26% Integrated Core Strategies (US) LLC 30 Sep 2025

As of 31 Dec 2025, 27 institutional investors reported holding 2,957,494 shares of CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX). This represents 20% of the company’s total 15,075,924 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX) together control 20% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Ikarian Capital, LLC 3.7% 555,932 0% 0.29% $2,212,609
RENAISSANCE TECHNOLOGIES LLC 3.1% 472,163 -8.4% 0% $1,879,209
VANGUARD GROUP INC 2.7% 411,786 0% 0% $1,638,909
PERCEPTIVE ADVISORS LLC 2.3% 341,087 0.02% $1,357,526
DIMENSIONAL FUND ADVISORS LP 1.8% 272,278 -3.1% 0% $1,083,667
BRIDGEWAY CAPITAL MANAGEMENT, LLC 1.1% 163,468 -13% 0.01% $650,603
BOOTHBAY FUND MANAGEMENT, LLC 0.85% 128,507 -24% 0.01% $511,458
GEODE CAPITAL MANAGEMENT, LLC 0.71% 107,274 +5.6% 0% $427,005
J. Goldman & Co LP 0.63% 94,541 -55% 0.01% $376,273
Bank of New York Mellon Corp 0.48% 72,513 0% 0% $288,602
BlackRock, Inc. 0.35% 52,577 +0.86% 0% $209,256
MARSHALL WACE, LLP 0.32% 48,137 0% $191,586
ACADIAN ASSET MANAGEMENT LLC 0.29% 44,288 0% 0% $176,000
STATE STREET CORP 0.22% 33,700 0% 0% $134,126
Heron Bay Capital Management 0.19% 29,189 -7.8% 0.02% $116,172
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.17% 26,038 0% $103,631
TWO SIGMA INVESTMENTS, LP 0.16% 24,485 -35% 0% $97,450
CITADEL ADVISORS LLC 0.15% 21,957 -47% 0% $87,389
NORTHERN TRUST CORP 0.13% 19,603 0% 0% $78,020
Cresset Asset Management, LLC 0.12% 17,475 -5.4% 0% $69,551
UBS Group AG 0.1% 15,386 +1760% 0% $61,237
MORGAN STANLEY 0.02% 3,260 -9.6% 0% $12,975
NewEdge Advisors, LLC 0.01% 1,203 +59% 0% $4,787
Capital Advisors, Ltd. LLC 0% 437 0% 0% $2,000
OSAIC HOLDINGS, INC. 0% 200 0% $796

Institutional Holders of CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 900,136 $2,924,086 -$1,528 $3.25 12
2025 Q4 2,957,494 $11,770,877 -$1,253,172 $3.98 27
2025 Q3 3,406,057 $10,626,381 -$866,501 $3.12 30
2025 Q2 3,682,268 $12,334,180 -$2,453,600 $3.35 30
2025 Q1 4,280,014 $18,146,545 +$10,361,899 $4.23 33
2024 Q4 1,842,038 $4,363,682 -$463,905 $2.37 20
2024 Q3 2,043,812 $2,614,244 -$42,881 $1.28 22
2024 Q2 2,077,457 $3,176,639 -$134,139 $1.53 22
2024 Q1 2,162,869 $3,632,852 -$59,437 $1.68 22
2023 Q4 2,197,513 $3,885,597 -$17,577 $1.79 23
2023 Q3 2,207,792 $4,170,727 -$310,716 $1.89 20
2023 Q2 2,399,098 $3,524,781 -$75,730 $1.47 21
2023 Q1 2,447,258 $4,771,188 -$92,987 $1.95 21
2022 Q4 2,493,007 $5,607,314 +$78,520 $2.25 22
2022 Q3 2,446,157 $5,893,000 -$555,959 $2.41 15
2022 Q2 2,708,341 $5,621,000 -$446,941 $2.08 20
2022 Q1 2,897,889 $8,171,000 -$99,570 $2.82 24
2021 Q4 2,835,251 $13,232,000 +$375,969 $4.67 23
2021 Q3 2,767,210 $7,429,000 -$468,259 $2.68 20
2021 Q2 2,937,884 $8,359,000 -$812,822 $2.84 24
2021 Q1 3,224,768 $9,769,000 -$1,950,699 $3.03 27
2020 Q4 3,875,161 $11,421,000 -$521,913 $2.95 24
2020 Q3 4,029,264 $12,934,000 -$360,904 $3.21 22
2020 Q2 4,141,182 $13,791,000 -$1,829,588 $3.33 23
2020 Q1 4,674,157 $16,964,000 +$754,442 $3.63 21
2019 Q4 4,458,508 $22,959,000 -$197,277 $5.15 23
2019 Q3 4,481,799 $26,572,000 -$1,733,892 $5.93 26
2019 Q2 4,768,946 $30,376,000 -$985,047 $6.37 22
2019 Q1 4,924,596 $28,610,000 -$352,915 $5.81 22
2018 Q4 4,984,289 $30,483,000 -$2,112,014 $6.03 22
2018 Q3 5,355,808 $30,579,000 -$33,832 $5.71 30
2018 Q2 5,365,571 $32,884,000 -$465,701 $6.13 29
2018 Q1 5,425,411 $36,242,000 -$49,479 $6.68 29
2017 Q4 5,430,722 $40,086,000 +$84,326 $7.36 31
2017 Q3 5,421,147 $38,274,000 -$194,328 $7.06 30
2017 Q2 5,449,601 $38,275,000 -$394,992 $7.00 33
2017 Q1 5,505,762 $38,201,000 +$3,117,539 $6.94 34
2016 Q4 5,481,400 $30,145,000 +$360,322 $5.50 37
2016 Q3 5,416,164 $27,128,000 +$892,622 $5.00 38
2016 Q2 5,240,228 $23,616,000 +$114,861 $4.50 41
2016 Q1 5,215,045 $23,413,000 -$94,079 $4.49 46
2015 Q4 5,128,280 $26,977,000 -$442,434 $5.26 44
2015 Q3 5,208,947 $30,053,000 +$44,760 $5.77 44
2015 Q2 5,201,315 $37,187,000 -$1,834,260 $7.15 44
2015 Q1 5,467,856 $36,368,000 -$1,516,917 $6.66 42
2014 Q4 5,716,701 $34,220,000 -$3,789,431 $5.98 42
2014 Q3 6,357,061 $31,401,000 -$1,425,255 $4.94 44
2014 Q2 6,670,341 $30,015,297 -$215,556 $4.50 44
2014 Q1 6,719,046 $30,230,294 +$106,519 $4.50 46
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .